Regeneron scores Phase III win with drug for rare cholesterol disorder

0
6
heart, doctor, cardiac


An analyst wrote that while the data are positive, the bigger question is how the drug will be priced, based on another drug already on the market for the same disease, HoFH, which affects about 1,300 people in the U.S.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here